Description
Indication & Scope
Erlotinib Hydrochloride Tablets (LuoRuiTe®) is an oral EGFR tyrosine kinase inhibitor targeted anti-tumor drug. It selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase activity, blocks downstream signal transduction, inhibits tumor cell proliferation, angiogenesis and metastasis, and induces tumor cell apoptosis.
- Mechanism
Selectively inhibit EGFR tyrosine kinase, block EGFR signal pathway, suppress tumor cell growth - Drug class
EGFR-TKI targeted anti-neoplastic agent / Oral targeted anti-cancer drug - Clinical use
EGFR sensitive mutation positive locally advanced / metastatic non-small cell lung cancer
| Generic Name | Erlotinib Hydrochloride Tablets |
| Brand Name | LuoRuiTe® |
| Ingredient | Erlotinib Hydrochloride |
| Dosage Form | Tablets |
| Package | 0.15g*7 tablets/box |
| Conditions Treated | Locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitive EGFR gene mutations, including first-line treatment, maintenance treatment, or second-line and above treatment after chemotherapy progression |
| Taboos | Hypersensitivity to erlotinib or any excipients of the formulation |
| Place of origin | Shanghai,China |
| Priscription Type | Prescription Drug |
| Storage Conditions | Seal tightly, store in a dry place, avoid direct sunlight |
| Manufacturer | Shanghai Chuangnuo Pharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | H20193262 |
| Date of Revision | July 17, 2026 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: 150mg once daily, taken orally on an empty stomach (at least 1 hour before meals or 2 hours after meals), taken whole without crushing, continue until disease progression or intolerable adverse reactions occur
Time: Fixed daily time, taken on an empty stomach
Interaction: Caution with CYP3A4 inhibitors/inducers (such as ketoconazole, rifampicin); avoid smoking which reduces drug exposure; monitor combined medications
Side effects: Rash, diarrhea, pruritus, dry skin, fatigue,anorexia, interstitial lung disease risk, liver function abnormality
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the key prerequisite for its application?
Confirm EGFR gene sensitive mutation in non-small cell lung cancer.
What is the most common adverse reaction?
Skin rash and diarrhea.
Does smoking affect the efficacy of erlotinib?
Yes, smoking significantly reduces drug exposure and efficacy.
What drug category does erlotinib belong to?
EGFR-TKI targeted anticancer drug.
LuoRuiTe® | Erlotinib Hydrochloride Tablets | NSCLC | DengYueRX
INN: Erlotinib Hydrochloride
Indications: NSCLC (non-small cell lung cancer)
Dosage Form: Tablets
Strength: 0.15g/Tablet
Original price was: $13.11.$11.14Current price is: $11.14.
